PCOS Hair Loss: Is It Androgenic Alopecia, or Something That Looks Like It?

5 min read · June 12, 2026

You notice it in the shower drain first. Then in your part line, which seems wider than it was last year. If you have PCOS — now PMOS, after a Lancet consensus paper renamed it in May 2026 — the easy assumption is that this is "the PCOS thing," your hormones thinning your hair, and there's nothing to do but wait.

That assumption is half right. PMOS does cause hair loss. But it does it in two distinct ways that look different, move on different timelines, and respond to different things — and on top of that, PMOS makes you more prone to a couple of look-alike causes that have nothing to do with androgens at all. Treating the wrong one is how people lose a year. Here's how to tell them apart.

---

The two ways PMOS thins hair

1. Androgenic alopecia (female pattern hair loss). This is the slow one. Excess androgen activity — high free testosterone, often made worse by the low SHBG common in PMOS — gradually miniaturizes hair follicles, especially across the crown and along the part. Hairs come back finer and shorter each cycle until some stop coming back. You don't see clumps falling out; you see the part widen and the ponytail thin. The 2019 Androgen Excess and PCOS Society report on female pattern hair loss confirmed it as a recognized feature of the condition, driven by follicle sensitivity to androgens rather than always by sky-high blood levels (J Clin Endocrinol Metab, 2019).

2. Telogen effluvium. This is the fast one. A metabolic or physiological shock — rapid weight loss, stopping the pill, a crash diet, a low-ferritin stretch, high stress — pushes a large share of follicles into the resting phase at once. Two to three months later they shed together. This is the version that fills the drain and scares people. It's diffuse, not patterned, and crucially it is usually self-limiting and reversible once the trigger is removed.

The reason this matters: a PMOS body is set up for both. The same insulin and weight dynamics that drive the androgen side also produce the exact shocks — post-pill rebound, rapid weight change — that trigger the shedding side. Many women have a little of each at once.

---

The look-alikes PMOS makes you more prone to

Before you assume "androgens," rule out two things PMOS women are statistically more likely to be carrying:

• Low iron / ferritin. Iron deficiency is one of the most common reversible contributors to diffuse hair loss in women, and the link runs specifically through ferritin — your iron stores — not just hemoglobin (J Am Acad Dermatol, 2006). Ferritin can sit low enough to shed hair while a standard "anemia" test still reads normal. A 2022 study found telogen effluvium patients clustered at the low-ferritin end (Dermatol Pract Concept, 2022).
• Thyroid dysfunction. An under- or over-active thyroid thins hair diffusely and is more common alongside PMOS. It's a simple panel to check and a common reason hair "won't respond" to androgen-focused efforts — because androgens were never the problem.

A 2019 review of vitamins and minerals in hair loss is blunt about the rest: outside of genuine iron and a few specific deficiencies, supplementing micronutrients you aren't actually low on does little (Dermatol Ther, 2019). The point of testing is to find the real lever, not to justify a shelf of pills.

---

How to tell which one you have

Three questions get you most of the way:

• Pattern. Widening part and crown thinning, gradual? Lean androgenic alopecia. Even, all-over shedding that came on suddenly? Lean telogen effluvium.
• Timeline. Crept up over a year or more? Androgenic. Started roughly 2–3 months after a clear event — going off the pill, a crash diet, an illness? That's the telogen effluvium delay, almost diagnostic on its own.
• The labs. Ask for ferritin (not just a full blood count), a thyroid panel (TSH), and the androgen markers that matter in PMOS — free testosterone and SHBG, not total testosterone alone. As our lean PMOS guide explains, low SHBG can leave androgens biologically active even when total testosterone reads "normal."

It's common to find more than one answer. A post-pill telogen shed sitting on top of slow androgenic thinning is a genuinely frequent picture, and it needs both addressed.

---

What actually helps depends on which it is

Telogen effluvium mostly resolves once the trigger is gone — restore ferritin, ease the weight crash, let a post-pill cycle settle — and regrowth follows over months. Androgenic alopecia is the patient one: lowering androgen activity slows further miniaturization, but already-shrunk follicles recover slowly and partially, over 6–12 months, often with a topical adjunct your doctor can discuss. The mechanism and the day-to-day of treating the androgen side — including why it's an endocrine issue and not a skincare one — sit on our acne and hair changes page.

What doesn't help is guessing. Hair loss is one of the most visible parts of PMOS and one of the most mistreated, because the fast scary version and the slow stubborn version get blended into one and managed wrong.

If you're not sure which you're dealing with, that's exactly the kind of thing our free 5-minute assessment is built to map — it reads your pattern across cycle, skin, weight, and hair and shows you where to start, without asking for anything in return.

Start the assessment →

---

This article is for informational purposes only and does not constitute medical advice. If your hair loss is sudden, patchy, or rapidly progressing, see a doctor — some causes need prompt evaluation.

References

1. Carmina, E., et al. (2019). Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab, 104(7), 2875–2891. https://pubmed.ncbi.nlm.nih.gov/30785992/
2. Trost, L.B., et al. (2006). The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol, 54(5), 824–844. https://pubmed.ncbi.nlm.nih.gov/16635664/
3. Evaluation of MCV/RDW Ratio and Correlations With Ferritin in Telogen Effluvium Patients. (2022). Dermatol Pract Concept. https://pubmed.ncbi.nlm.nih.gov/36159144/
4. Almohanna, H.M., et al. (2019). The Role of Vitamins and Minerals in Hair Loss: A Review. Dermatol Ther (Heidelb), 9(1), 51–70. https://pubmed.ncbi.nlm.nih.gov/30547302/
5. Teede, H.J., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. https://doi.org/10.1016/S0140-6736(26)00717-8